CJC1295 NO DAC 5mg + Ipamorelin 5mg

Both are the same modified 29-amino-acid fragment of growth-hormone-releasing hormone, GHRH(1-29), with four amino-acid substitutions that resist enzymatic breakdown. CJC-1295 DAC adds a Drug Affinity Complex (a maleimidopropionyl linker on the C-terminal lysine) that bonds to albumin, giving it a much longer half-life in research models. The no-DAC version, also called modified GRF(1-29), lacks the linker and is cleared quickly.

A vial containing two or more peptides that were combined in solution in a set ratio and then freeze-dried together. The label states the mass of each component. Testing a blend is more involved than testing a single peptide: HPLC has to resolve each component as its own peak, and mass spectrometry should confirm each expected molecular weight.

No. HGH is the 191-amino-acid growth hormone itself. Ipamorelin, GHRP-6, hexarelin, sermorelin, CJC-1295 and tesamorelin are much smaller synthetic peptides, called growth hormone secretagogues, that act on pituitary receptors controlling the body's own release of growth hormone: the ghrelin receptor (GHS-R1a) or the GHRH receptor. None of them contains the growth hormone sequence.

Sermorelin, CJC-1295 and tesamorelin are all GHRH analogues acting on the GHRH receptor: sermorelin is the native 29-amino-acid fragment, CJC-1295 (no DAC) is that fragment with four stabilizing substitutions, and tesamorelin is the full 44-residue sequence with an N-terminal hexenoyl group. The CJC-1295/ipamorelin blend adds a second compound, ipamorelin, which acts on a different receptor, the ghrelin receptor (GHS-R1a).

No. CJC-1295 is a 29-residue GHRH analogue that acts on the GHRH receptor; the DAC version adds an albumin-binding linker. Ipamorelin is a 5-amino-acid peptide that acts on a different receptor, the ghrelin receptor (GHS-R1a). The two are unrelated in sequence, which is why they are often supplied together: they act on the two separate receptor pathways that regulate pituitary growth hormone release.

MK-677 (ibutamoren) is not a peptide: it is a small-molecule ghrelin-receptor agonist developed by Merck in the 1990s. Ipamorelin and GHRP-6 are peptides that act on that same ghrelin receptor (GHS-R1a), while CJC-1295 acts on a different one, the GHRH receptor. None of these is FDA approved. We do not sell MK-677.

In the United States, CJC-1295 is not a controlled substance and can be lawfully purchased as a research chemical for laboratory use. It is not an approved drug, so selling it for human use or with health claims is unlawful. The World Anti-Doping Agency names CJC-1295 among the GHRH analogues in class S2, prohibited in sport at all times. This is general information, not legal advice.

A single vial in which CJC-1295 without DAC (modified GRF 1-29) and ipamorelin were dissolved together in a fixed ratio and freeze-dried, so both peptides are present as one powder: 5 mg of each in ours. CJC-1295 no DAC is a 29-residue GHRH analogue; ipamorelin is a 5-residue ghrelin-receptor agonist. The lot's Certificate of Analysis reports each component.

Because they act on complementary receptor targets. Pituitary growth hormone release is regulated by two separate receptor pathways: the GHRH receptor, targeted by CJC-1295, and the ghrelin receptor (GHS-R1a), targeted by ipamorelin. Researchers studying how the two pathways interact often use one compound from each class, so a co-lyophilized vial offers both in a fixed ratio. A blend is a convenience format, not an approved product.

Each component has its own literature. Ipamorelin was studied by Novo Nordisk as a selective ghrelin-receptor agonist, in rodent models and later in human clinical trials. CJC-1295 belongs to the GHRH-analogue research on GHRH receptor signaling. Published research on the two together as a combination is sparse, and the blend has never been through clinical development. Findings in cells or animals do not establish effects in people.

No. Neither CJC-1295 (with or without DAC) nor ipamorelin has been approved by the FDA, and no combination of the two is an approved product. Both are research compounds; the blend sold here is for laboratory research use only, not for human or veterinary use.

The blend fixes a 1:1 mass ratio (5 mg + 5 mg) in one vial, which saves a reconstitution step and keeps the ratio identical across experiments. Separate vials let a researcher vary each peptide independently, run single-compound controls, and switch between CJC-1295 with or without DAC. Choose separate vials when the experiment needs either compound on its own.

Each component is verified separately within the same sample. HPLC must resolve CJC-1295 and ipamorelin as two distinct peaks, which is straightforward because they differ greatly in size (29 versus 5 amino acids). Mass spectrometry should show each expected molecular weight, about 3,368 Da for modified GRF(1-29) and about 712 Da for ipamorelin. The Certificate of Analysis reports both components.

Like any lyophilized peptide blend: let the sealed vial reach room temperature, add sterile diluent slowly down the inside wall, and swirl gently until dissolved, without shaking. Each component's concentration is its own labeled mass divided by the volume added, so a 5 mg + 5 mg vial holds both peptides at the same concentration; the total 10 mg is split between them. Label the vial with the date and both concentrations, and refrigerate it.

Yes, for storage. Keep the sealed lyophilized blend at 2–8 °C, or frozen at −20 °C for long-term storage, away from light and moisture. Once reconstituted, keep it refrigerated and avoid freeze-thaw cycles. The blend's stability is limited by its less stable component, so use it within the window stated on the label or Certificate of Analysis.

They sit at different points of the growth hormone axis. CJC-1295, sermorelin and tesamorelin (GHRH receptor) and ipamorelin, GHRP-6 and hexarelin (ghrelin receptor) are small peptides that act on pituitary receptors controlling growth hormone release. IGF-1 LR3 acts further downstream: it is an analogue of IGF-1, the hormone produced largely in response to growth hormone, and binds the IGF-1 receptor directly.

Yes. Each lot has its own Certificate of Analysis, linked on this page for the current lot of each size: (5mg+5mg) (99.74% HPLC purity). Past certificates are archived in the COA library; contact us with the lot number on the vial label if a certificate is missing.

99.74% (HPLC, current lot). Purity is measured by high-performance liquid chromatography (HPLC) and reported on the lot's Certificate of Analysis.

CJC1295 NO DAC 5mg + Ipamorelin 5mg is supplied as lyophilized powder in a sealed vial: (5mg+5mg). In stock and dispatched in 1–2 business days. Quantity pricing applies automatically at 5+ and 10+ vials of the same size.

Store sealed at −20 °C, dry and protected from light.